WO2001081316A2 - Inhibiteurs de phenyle farnesyltransferase substitues - Google Patents
Inhibiteurs de phenyle farnesyltransferase substitues Download PDFInfo
- Publication number
- WO2001081316A2 WO2001081316A2 PCT/US2001/013678 US0113678W WO0181316A2 WO 2001081316 A2 WO2001081316 A2 WO 2001081316A2 US 0113678 W US0113678 W US 0113678W WO 0181316 A2 WO0181316 A2 WO 0181316A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- imidazol
- group
- desired product
- compound according
- Prior art date
Links
- 0 *c(cc1C*(Cc(cc2)cc(-c3cccc4c3cccc4)c2C#N)Cc2cccnc2)ccc1O Chemical compound *c(cc1C*(Cc(cc2)cc(-c3cccc4c3cccc4)c2C#N)Cc2cccnc2)ccc1O 0.000 description 42
- LQCJAZFXKUSGPU-UHFFFAOYSA-N Cc(cccc1)c1-c(cc(C(CCc1ccccc1)(c1cnc[s]1)O)cc1)c1C#N Chemical compound Cc(cccc1)c1-c(cc(C(CCc1ccccc1)(c1cnc[s]1)O)cc1)c1C#N LQCJAZFXKUSGPU-UHFFFAOYSA-N 0.000 description 2
- ADFZHNSHKXRYJT-UHFFFAOYSA-N Cc(cccc1)c1-c(cc(C(c1cnc[s]1)OCc1ccccc1)cc1)c1Cl Chemical compound Cc(cccc1)c1-c(cc(C(c1cnc[s]1)OCc1ccccc1)cc1)c1Cl ADFZHNSHKXRYJT-UHFFFAOYSA-N 0.000 description 2
- YANJOENKWGQVGM-UHFFFAOYSA-N CC(C)(C)OC(N1CCC(CC(C2=CN=CC3C2C3)c(cc2)cc(-c3cccc4c3cccc4)c2C#N)CC1)=C Chemical compound CC(C)(C)OC(N1CCC(CC(C2=CN=CC3C2C3)c(cc2)cc(-c3cccc4c3cccc4)c2C#N)CC1)=C YANJOENKWGQVGM-UHFFFAOYSA-N 0.000 description 1
- CMJOPNBZGZGLNO-UHFFFAOYSA-N CC(C1)C(C(c2cnc[s]2)OCc2ccccc2)=CC(c2ccccc2)=C1C#N Chemical compound CC(C1)C(C(c2cnc[s]2)OCc2ccccc2)=CC(c2ccccc2)=C1C#N CMJOPNBZGZGLNO-UHFFFAOYSA-N 0.000 description 1
- QGGTXGSHQIRZDS-UHFFFAOYSA-N CC(Nc1ccc(CNC(c2cnc[s]2)c(cc2)cc(-c3cccc4c3cccc4)c2C#N)cc1)=O Chemical compound CC(Nc1ccc(CNC(c2cnc[s]2)c(cc2)cc(-c3cccc4c3cccc4)c2C#N)cc1)=O QGGTXGSHQIRZDS-UHFFFAOYSA-N 0.000 description 1
- FKSSCRWDQKVFQO-UHFFFAOYSA-N CC1(CN(CC2CCCCC2)Cc(cc2-c3cccc4c3cccc4)ccc2C#N)C=CC=NC1 Chemical compound CC1(CN(CC2CCCCC2)Cc(cc2-c3cccc4c3cccc4)ccc2C#N)C=CC=NC1 FKSSCRWDQKVFQO-UHFFFAOYSA-N 0.000 description 1
- BGJOERDFXQQGNT-UHFFFAOYSA-N CCCC1CCC(CN(Cc2cnc[s]2)Cc(cc2-c3cccc4c3cccc4)ccc2C#N)CC1 Chemical compound CCCC1CCC(CN(Cc2cnc[s]2)Cc(cc2-c3cccc4c3cccc4)ccc2C#N)CC1 BGJOERDFXQQGNT-UHFFFAOYSA-N 0.000 description 1
- GMOPJFXHVPFAOI-UHFFFAOYSA-N CN(Cc1cccnc1)c(cc1-c2cccc3c2cccc3)ccc1C#N Chemical compound CN(Cc1cccnc1)c(cc1-c2cccc3c2cccc3)ccc1C#N GMOPJFXHVPFAOI-UHFFFAOYSA-N 0.000 description 1
- SWCVYXZCFDPCNE-UHFFFAOYSA-N COC(c1cc(CN(Cc2cccnc2)c(cc2-c3cccc4c3cccc4)ccc2C#N)ccc1)=O Chemical compound COC(c1cc(CN(Cc2cccnc2)c(cc2-c3cccc4c3cccc4)ccc2C#N)ccc1)=O SWCVYXZCFDPCNE-UHFFFAOYSA-N 0.000 description 1
- GRPGKRQAGPCOBP-UHFFFAOYSA-N COC(c1ccc(CNC(c2cnc[s]2)c(cc2)cc(-c3cccc4c3cccc4)c2C#N)nc1)=O Chemical compound COC(c1ccc(CNC(c2cnc[s]2)c(cc2)cc(-c3cccc4c3cccc4)c2C#N)nc1)=O GRPGKRQAGPCOBP-UHFFFAOYSA-N 0.000 description 1
- CPTRUDLWTJMQKP-UHFFFAOYSA-N COC(c1ccc(COC(c(cc2)cc(-c3c(C(F)(F)F)cccc3)c2C#N)c2cccnc2)nc1)=O Chemical compound COC(c1ccc(COC(c(cc2)cc(-c3c(C(F)(F)F)cccc3)c2C#N)c2cccnc2)nc1)=O CPTRUDLWTJMQKP-UHFFFAOYSA-N 0.000 description 1
- JXLQQLZTZJBBIC-UHFFFAOYSA-N Cc(cc1)ccc1-c(cc(C(c1cnc[s]1)OCc1ccccc1)cc1)c1C#N Chemical compound Cc(cc1)ccc1-c(cc(C(c1cnc[s]1)OCc1ccccc1)cc1)c1C#N JXLQQLZTZJBBIC-UHFFFAOYSA-N 0.000 description 1
- KZJZCYNECABLSQ-UHFFFAOYSA-N Cc(cc1-c2cccc3c2cccc3)ccc1C#N Chemical compound Cc(cc1-c2cccc3c2cccc3)ccc1C#N KZJZCYNECABLSQ-UHFFFAOYSA-N 0.000 description 1
- VXTHEJBHVVHOTC-UHFFFAOYSA-N Cc(cccc1)c1-c(cc(C(c1cccnc1)OCc(cc1)ccc1C(NC)=O)cc1)c1C#N Chemical compound Cc(cccc1)c1-c(cc(C(c1cccnc1)OCc(cc1)ccc1C(NC)=O)cc1)c1C#N VXTHEJBHVVHOTC-UHFFFAOYSA-N 0.000 description 1
- CUHKAGKNOOECHS-UHFFFAOYSA-N Cc(cccc1)c1-c(cc(C(c1cccnc1)OCc1cc([N+]([O-])=O)ccc1OC)cc1)c1C#N Chemical compound Cc(cccc1)c1-c(cc(C(c1cccnc1)OCc1cc([N+]([O-])=O)ccc1OC)cc1)c1C#N CUHKAGKNOOECHS-UHFFFAOYSA-N 0.000 description 1
- WSZPKXXOIBFHIM-UHFFFAOYSA-N Cc(cccc1)c1-c(cc(C(c1cnc[s]1)(C#Cc1ccccc1)O)cc1)c1C#N Chemical compound Cc(cccc1)c1-c(cc(C(c1cnc[s]1)(C#Cc1ccccc1)O)cc1)c1C#N WSZPKXXOIBFHIM-UHFFFAOYSA-N 0.000 description 1
- VWHVORUVLCIZND-UHFFFAOYSA-N Cc(cccc1)c1-c(cc(C(c1cnc[s]1)OCc(c(Cl)c1)cc2c1OCO2)cc1)c1C#N Chemical compound Cc(cccc1)c1-c(cc(C(c1cnc[s]1)OCc(c(Cl)c1)cc2c1OCO2)cc1)c1C#N VWHVORUVLCIZND-UHFFFAOYSA-N 0.000 description 1
- HWFAUUWPIXJBNB-UHFFFAOYSA-N Cc(cccc1)c1-c(cc(C(c1cnc[s]1)OCc(cc1)ccc1C(N(C)C)=O)cc1)c1C#N Chemical compound Cc(cccc1)c1-c(cc(C(c1cnc[s]1)OCc(cc1)ccc1C(N(C)C)=O)cc1)c1C#N HWFAUUWPIXJBNB-UHFFFAOYSA-N 0.000 description 1
- VDVMSKPKVJYASG-UHFFFAOYSA-N Cc(cccc1)c1-c(cc(C(c1cnc[s]1)OCc(cc1)ccc1S(C)(=O)=O)cc1)c1C#N Chemical compound Cc(cccc1)c1-c(cc(C(c1cnc[s]1)OCc(cc1)ccc1S(C)(=O)=O)cc1)c1C#N VDVMSKPKVJYASG-UHFFFAOYSA-N 0.000 description 1
- MMCKYQYZYWWLEO-UHFFFAOYSA-N Cc(cccc1)c1-c(cc(C(c1cnc[s]1)OCc(ccc(Cl)c1)c1Cl)cc1)c1C#N Chemical compound Cc(cccc1)c1-c(cc(C(c1cnc[s]1)OCc(ccc(Cl)c1)c1Cl)cc1)c1C#N MMCKYQYZYWWLEO-UHFFFAOYSA-N 0.000 description 1
- IXBPJQAEGCEDHF-UHFFFAOYSA-N Cc(cccc1)c1-c(cc(C(c1cnc[s]1)OCc(ccc(Cl)c1)c1[N+]([O-])=O)cc1)c1C#N Chemical compound Cc(cccc1)c1-c(cc(C(c1cnc[s]1)OCc(ccc(Cl)c1)c1[N+]([O-])=O)cc1)c1C#N IXBPJQAEGCEDHF-UHFFFAOYSA-N 0.000 description 1
- DGIHBGMXXMOSIT-UHFFFAOYSA-N Cc(cccc1)c1-c(cc(C(c1cnc[s]1)OCc1c2ncccc2ccc1)cc1)c1C#N Chemical compound Cc(cccc1)c1-c(cc(C(c1cnc[s]1)OCc1c2ncccc2ccc1)cc1)c1C#N DGIHBGMXXMOSIT-UHFFFAOYSA-N 0.000 description 1
- DLDNWJYEGZQANA-UHFFFAOYSA-N Cc(cccc1)c1-c(cc(C(c1cnc[s]1)OCc1cc(OC(F)(F)F)ccc1)cc1)c1C#N Chemical compound Cc(cccc1)c1-c(cc(C(c1cnc[s]1)OCc1cc(OC(F)(F)F)ccc1)cc1)c1C#N DLDNWJYEGZQANA-UHFFFAOYSA-N 0.000 description 1
- UOWRKFNNAYYGQH-UHFFFAOYSA-N Cc(cccc1)c1-c(cc(CN(CCC1CCCCC1)CC1=CN=CC1)cc1)c1C#N Chemical compound Cc(cccc1)c1-c(cc(CN(CCC1CCCCC1)CC1=CN=CC1)cc1)c1C#N UOWRKFNNAYYGQH-UHFFFAOYSA-N 0.000 description 1
- IKLPYQCOBIRLEV-UHFFFAOYSA-N Cc(cccc1)c1-c(cc(cc1)C(c2cnc[s]2)=O)c1C#N Chemical compound Cc(cccc1)c1-c(cc(cc1)C(c2cnc[s]2)=O)c1C#N IKLPYQCOBIRLEV-UHFFFAOYSA-N 0.000 description 1
- KPRGEQPOQRHWQS-UHFFFAOYSA-N Cc(cccc1)c1-c(cc(cc1)N(Cc2cnc[s]2)Cc2cc(C#N)ccc2)c1C#N Chemical compound Cc(cccc1)c1-c(cc(cc1)N(Cc2cnc[s]2)Cc2cc(C#N)ccc2)c1C#N KPRGEQPOQRHWQS-UHFFFAOYSA-N 0.000 description 1
- JSQIYHWNNHIBST-UHFFFAOYSA-N Cc(cccc1)c1-c1cc(N(Cc2cnc[s]2)C(c2ccccc2)=O)ccc1C#N Chemical compound Cc(cccc1)c1-c1cc(N(Cc2cnc[s]2)C(c2ccccc2)=O)ccc1C#N JSQIYHWNNHIBST-UHFFFAOYSA-N 0.000 description 1
- WOLJXLGYQZVVFE-UHFFFAOYSA-N Cc1cc(C(F)(F)F)c(CCC(c(cc2)cc(-c3c(C)cccc3)c2C#N)c2cccnc2)cc1 Chemical compound Cc1cc(C(F)(F)F)c(CCC(c(cc2)cc(-c3c(C)cccc3)c2C#N)c2cccnc2)cc1 WOLJXLGYQZVVFE-UHFFFAOYSA-N 0.000 description 1
- XOMKAMIQNIAVMT-UHFFFAOYSA-N Cc1cccc(-c2cc(C(c3cccnc3)OCc(cc3)ccc3C#N)ccc2C#N)c1C Chemical compound Cc1cccc(-c2cc(C(c3cccnc3)OCc(cc3)ccc3C#N)ccc2C#N)c1C XOMKAMIQNIAVMT-UHFFFAOYSA-N 0.000 description 1
- PTIGZFVZXAJZFC-UHFFFAOYSA-N Cc1cccc(COC(c2cnc[s]2)c(cc2)cc(-c3c(C)cccc3)c2C#N)c1 Chemical compound Cc1cccc(COC(c2cnc[s]2)c(cc2)cc(-c3c(C)cccc3)c2C#N)c1 PTIGZFVZXAJZFC-UHFFFAOYSA-N 0.000 description 1
- BANWEWVKDVEPDE-UHFFFAOYSA-N N#Cc(c(-c1cccc2c1cccc2)c1)ccc1NCc1cnc[s]1 Chemical compound N#Cc(c(-c1cccc2c1cccc2)c1)ccc1NCc1cnc[s]1 BANWEWVKDVEPDE-UHFFFAOYSA-N 0.000 description 1
- JBHOBIOLOMNUTC-UHFFFAOYSA-N N#Cc(c(-c1cccc2c1nccc2)c1)ccc1C(c1cnc[s]1)=O Chemical compound N#Cc(c(-c1cccc2c1nccc2)c1)ccc1C(c1cnc[s]1)=O JBHOBIOLOMNUTC-UHFFFAOYSA-N 0.000 description 1
- WFSAMCREZYKMNB-UHFFFAOYSA-N N#Cc(ccc(C(C1CC1)(c1cnc[s]1)C#Cc1ccccc1)c1)c1-c1cccc2c1cccc2 Chemical compound N#Cc(ccc(C(C1CC1)(c1cnc[s]1)C#Cc1ccccc1)c1)c1-c1cccc2c1cccc2 WFSAMCREZYKMNB-UHFFFAOYSA-N 0.000 description 1
- PEKLEKNQEUHRGM-UHFFFAOYSA-N N#Cc(ccc(C(c1cnc[s]1)NC(CC1)CCN1C(c1ccccc1)=O)c1)c1-c1cccc2c1cccc2 Chemical compound N#Cc(ccc(C(c1cnc[s]1)NC(CC1)CCN1C(c1ccccc1)=O)c1)c1-c1cccc2c1cccc2 PEKLEKNQEUHRGM-UHFFFAOYSA-N 0.000 description 1
- RQGOSINVQSKIQN-UHFFFAOYSA-N N#Cc(ccc(C(c1cnc[s]1)OCc(cc1)cc(Cl)c1Cl)c1)c1-c1c2ncccc2ccc1 Chemical compound N#Cc(ccc(C(c1cnc[s]1)OCc(cc1)cc(Cl)c1Cl)c1)c1-c1c2ncccc2ccc1 RQGOSINVQSKIQN-UHFFFAOYSA-N 0.000 description 1
- UNNIUDCBUWVBBQ-UHFFFAOYSA-N N#Cc(ccc(C(c1cnc[s]1)OCc(cc1)ccc1C(O)=O)c1)c1-c1cccc2c1nccc2 Chemical compound N#Cc(ccc(C(c1cnc[s]1)OCc(cc1)ccc1C(O)=O)c1)c1-c1cccc2c1nccc2 UNNIUDCBUWVBBQ-UHFFFAOYSA-N 0.000 description 1
- UVZUJSCISOYQOS-UHFFFAOYSA-N N#Cc(ccc(C(c1cnc[s]1)OCc(cc1F)ccc1C#N)c1)c1-c1cccc2c1cccc2 Chemical compound N#Cc(ccc(C(c1cnc[s]1)OCc(cc1F)ccc1C#N)c1)c1-c1cccc2c1cccc2 UVZUJSCISOYQOS-UHFFFAOYSA-N 0.000 description 1
- DQADGLKTJSJFDV-UHFFFAOYSA-N N#Cc(ccc(C(c1cnc[s]1)OCc1cc(F)c(C(F)(F)F)cc1)c1)c1-c1cccc2c1nccc2 Chemical compound N#Cc(ccc(C(c1cnc[s]1)OCc1cc(F)c(C(F)(F)F)cc1)c1)c1-c1cccc2c1nccc2 DQADGLKTJSJFDV-UHFFFAOYSA-N 0.000 description 1
- FDKSZRRPQGPOEG-UHFFFAOYSA-N N#Cc(ccc(C(c1cnc[s]1)OCc1ccccc1)c1)c1-c1c[s]cc1 Chemical compound N#Cc(ccc(C(c1cnc[s]1)OCc1ccccc1)c1)c1-c1c[s]cc1 FDKSZRRPQGPOEG-UHFFFAOYSA-N 0.000 description 1
- UTYJYHHDVANILX-UHFFFAOYSA-N N#Cc(ccc(C(c1cnc[s]1)OCc1ccccc1)c1)c1-c1cc(cccc2)c2cc1 Chemical compound N#Cc(ccc(C(c1cnc[s]1)OCc1ccccc1)c1)c1-c1cc(cccc2)c2cc1 UTYJYHHDVANILX-UHFFFAOYSA-N 0.000 description 1
- PCVIXCFSWKIQLN-UHFFFAOYSA-N N#Cc(ccc(C(c1cnc[s]1)OCc1ccccc1)c1)c1-c1cncc2c1cccc2 Chemical compound N#Cc(ccc(C(c1cnc[s]1)OCc1ccccc1)c1)c1-c1cncc2c1cccc2 PCVIXCFSWKIQLN-UHFFFAOYSA-N 0.000 description 1
- SOKMSYMVHVICCT-UHFFFAOYSA-N N#Cc(ccc(CN(CCC1CCCCC1)Cc1cnc[s]1)c1)c1-c1cccc2c1cccc2 Chemical compound N#Cc(ccc(CN(CCC1CCCCC1)Cc1cnc[s]1)c1)c1-c1cccc2c1cccc2 SOKMSYMVHVICCT-UHFFFAOYSA-N 0.000 description 1
- WRJSZQUUHKIGDD-UHFFFAOYSA-N N#Cc(ccc(N(Cc1cnc[s]1)C(c1ccccc1)=O)c1)c1-c1cccc2c1cccc2 Chemical compound N#Cc(ccc(N(Cc1cnc[s]1)C(c1ccccc1)=O)c1)c1-c1cccc2c1cccc2 WRJSZQUUHKIGDD-UHFFFAOYSA-N 0.000 description 1
- ISVJPLWXFJTPNN-UHFFFAOYSA-N N#Cc1ccc(C(c2cnc[s]2)(C#Cc2ccccc2)O)cc1-c1cccc2c1cccc2 Chemical compound N#Cc1ccc(C(c2cnc[s]2)(C#Cc2ccccc2)O)cc1-c1cccc2c1cccc2 ISVJPLWXFJTPNN-UHFFFAOYSA-N 0.000 description 1
- OIZANAOWBVQMLX-UHFFFAOYSA-N N#Cc1ccc(CCC(CCc(cc2)cc(-c3cccc4c3cccc4)c2C#N)Cc2cnc[s]2)nc1 Chemical compound N#Cc1ccc(CCC(CCc(cc2)cc(-c3cccc4c3cccc4)c2C#N)Cc2cnc[s]2)nc1 OIZANAOWBVQMLX-UHFFFAOYSA-N 0.000 description 1
- BFHJYAVGPYPMGS-UHFFFAOYSA-N N#Cc1ccc(CCC(c(cc2)cc(-c(cccc3Cl)c3Cl)c2C#N)c2cccnc2)cc1 Chemical compound N#Cc1ccc(CCC(c(cc2)cc(-c(cccc3Cl)c3Cl)c2C#N)c2cccnc2)cc1 BFHJYAVGPYPMGS-UHFFFAOYSA-N 0.000 description 1
- VWMVMOOYMNUHMA-UHFFFAOYSA-N N#Cc1ccc(CNC(c2cnc[s]2)c(cc2)cc(-c3cccc4c3cccc4)c2C#N)nc1 Chemical compound N#Cc1ccc(CNC(c2cnc[s]2)c(cc2)cc(-c3cccc4c3cccc4)c2C#N)nc1 VWMVMOOYMNUHMA-UHFFFAOYSA-N 0.000 description 1
- LABNJJVRCSTFDL-UHFFFAOYSA-N N#Cc1ccc(COC(c(cc2)cc(-c3ccccc3C(O)=O)c2C#N)c2cccnc2)cc1 Chemical compound N#Cc1ccc(COC(c(cc2)cc(-c3ccccc3C(O)=O)c2C#N)c2cccnc2)cc1 LABNJJVRCSTFDL-UHFFFAOYSA-N 0.000 description 1
- DIJKCVRBXLJZNR-UHFFFAOYSA-N N#Cc1ccc(COC(c(cc2-c3c(C=O)cccc3)ccc2C#N)c2cccnc2)cc1 Chemical compound N#Cc1ccc(COC(c(cc2-c3c(C=O)cccc3)ccc2C#N)c2cccnc2)cc1 DIJKCVRBXLJZNR-UHFFFAOYSA-N 0.000 description 1
- REZQOCQHNXCEGA-UHFFFAOYSA-N N#Cc1ccc(COC(c2cnc[s]2)c(cc2)cc(-c(cccc3)c3-c3ccccc3)c2C#N)cc1 Chemical compound N#Cc1ccc(COC(c2cnc[s]2)c(cc2)cc(-c(cccc3)c3-c3ccccc3)c2C#N)cc1 REZQOCQHNXCEGA-UHFFFAOYSA-N 0.000 description 1
- OTJXWHGWSFIASQ-UHFFFAOYSA-N N#Cc1ccc(COC(c2cnc[s]2)c(cc2-c3c(C=O)cccc3)ccc2C#N)cc1 Chemical compound N#Cc1ccc(COC(c2cnc[s]2)c(cc2-c3c(C=O)cccc3)ccc2C#N)cc1 OTJXWHGWSFIASQ-UHFFFAOYSA-N 0.000 description 1
- MIARIKUHXQOGJS-UHFFFAOYSA-N N#Cc1ccc(COC(c2cnc[s]2)c(cc2-c3cccc4c3cccc4)ccc2C#N)cc1 Chemical compound N#Cc1ccc(COC(c2cnc[s]2)c(cc2-c3cccc4c3cccc4)ccc2C#N)cc1 MIARIKUHXQOGJS-UHFFFAOYSA-N 0.000 description 1
- FLPHRRNHDPHQTA-UHFFFAOYSA-N N#Cc1ccc(CS(C(c2cnc[s]2)c(cc2-c3c(cccc4)c4ccc3)ccc2C#N)(=O)=O)cc1 Chemical compound N#Cc1ccc(CS(C(c2cnc[s]2)c(cc2-c3c(cccc4)c4ccc3)ccc2C#N)(=O)=O)cc1 FLPHRRNHDPHQTA-UHFFFAOYSA-N 0.000 description 1
- DKGPVIHWUJSLFP-UHFFFAOYSA-N N#Cc1cccc(NC(c(cc2-c3cccc4c3cccc4)ccc2C#N)c2cccnc2)c1 Chemical compound N#Cc1cccc(NC(c(cc2-c3cccc4c3cccc4)ccc2C#N)c2cccnc2)c1 DKGPVIHWUJSLFP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001578410A JP2004509064A (ja) | 2000-04-27 | 2001-04-25 | 置換フェニルファルネシルトランスフェラーゼ阻害剤 |
AU2001259218A AU2001259218A1 (en) | 2000-04-27 | 2001-04-25 | Substituted phenyl farnesyltransferase inhibitors |
CA002407093A CA2407093A1 (fr) | 2000-04-27 | 2001-04-25 | Inhibiteurs de phenyle farnesyltransferase substitues |
EP01932712A EP1276726A2 (fr) | 2000-04-27 | 2001-04-25 | Inhibiteurs de phenyle farnesyltransferase substitues |
MXPA02010608A MXPA02010608A (es) | 2000-04-27 | 2001-04-25 | Inhibidores de farnesiltransferasa sustituidos con fenilo. |
HK03104500.2A HK1053833A1 (zh) | 2000-04-27 | 2003-06-23 | 取代苯基法呢基轉移酶抑制劑 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56325600A | 2000-04-27 | 2000-04-27 | |
US09/563,256 | 2000-04-27 | ||
US82220501A | 2001-04-02 | 2001-04-02 | |
US09/822,205 | 2001-04-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001081316A2 true WO2001081316A2 (fr) | 2001-11-01 |
WO2001081316A3 WO2001081316A3 (fr) | 2002-05-23 |
Family
ID=27073227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/013678 WO2001081316A2 (fr) | 2000-04-27 | 2001-04-25 | Inhibiteurs de phenyle farnesyltransferase substitues |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1276726A2 (fr) |
JP (1) | JP2004509064A (fr) |
AU (1) | AU2001259218A1 (fr) |
CA (1) | CA2407093A1 (fr) |
HK (1) | HK1053833A1 (fr) |
MX (1) | MXPA02010608A (fr) |
PE (1) | PE20011318A1 (fr) |
WO (1) | WO2001081316A2 (fr) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003051366A2 (fr) | 2001-12-13 | 2003-06-26 | Abbott Laboratories | Inhibiteurs de kinase |
WO2004037791A1 (fr) | 2002-10-21 | 2004-05-06 | Chiron Corporation | Inhibiteurs de glycogene synthase kinase 3 |
JP2005511790A (ja) * | 2001-12-19 | 2005-04-28 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ファルネシルトランスフェラーゼ阻害剤としての炭素連結トリアゾールで置換されている1,8−アネル化キノリン誘導体 |
EP1734957A2 (fr) * | 2004-04-01 | 2006-12-27 | Pfizer Products Inc. | Composes de thiazole sulfamide utiles pour le traitement des maladies neurodegeneratives |
US7179827B2 (en) | 2004-03-31 | 2007-02-20 | Lexicon Genetics Incorporated | Thiazoles and methods of their use |
US7745638B2 (en) | 2003-07-22 | 2010-06-29 | Astex Therapeutics Limited | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators |
US8013163B2 (en) | 2005-01-21 | 2011-09-06 | Astex Therapeutics Limited | 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors |
US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
US8710043B2 (en) | 2011-06-24 | 2014-04-29 | Amgen Inc. | TRPM8 antagonists and their use in treatments |
US8778941B2 (en) | 2011-06-24 | 2014-07-15 | Amgen Inc. | TRPM8 antagonists and their use in treatments |
US8952161B2 (en) | 2007-04-06 | 2015-02-10 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
US11299467B2 (en) | 2017-07-21 | 2022-04-12 | Antabio Sas | Chemical compounds |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200806284A (en) * | 2006-03-31 | 2008-02-01 | Alcon Mfg Ltd | Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma |
JP2021527125A (ja) * | 2018-06-07 | 2021-10-11 | ディサーム・セラピューティクス・インコーポレイテッドDisarm Therapeutics, Inc. | Sarm1阻害剤 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0079191A1 (fr) * | 1981-11-06 | 1983-05-18 | Imperial Chemical Industries Plc | Dérivés d'amide |
WO1998029199A1 (fr) * | 1996-12-31 | 1998-07-09 | Wayne Pigment Corp. | Composition pigmentaire inhibant les taches |
WO1999017777A1 (fr) * | 1997-10-08 | 1999-04-15 | Merck & Co., Inc. | Inhibiteurs de transferase de prenyl-proteine |
WO2000001382A1 (fr) * | 1998-07-02 | 2000-01-13 | Merck & Co., Inc. | Inhibiteurs de prenyl-proteine transferase |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2868883B2 (ja) * | 1990-10-15 | 1999-03-10 | 株式会社トクヤマ | ジオキソラン誘導体 |
-
2001
- 2001-04-25 CA CA002407093A patent/CA2407093A1/fr not_active Abandoned
- 2001-04-25 WO PCT/US2001/013678 patent/WO2001081316A2/fr not_active Application Discontinuation
- 2001-04-25 MX MXPA02010608A patent/MXPA02010608A/es unknown
- 2001-04-25 JP JP2001578410A patent/JP2004509064A/ja not_active Withdrawn
- 2001-04-25 AU AU2001259218A patent/AU2001259218A1/en not_active Abandoned
- 2001-04-25 EP EP01932712A patent/EP1276726A2/fr not_active Withdrawn
- 2001-04-27 PE PE2001000384A patent/PE20011318A1/es not_active Application Discontinuation
-
2003
- 2003-06-23 HK HK03104500.2A patent/HK1053833A1/zh unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0079191A1 (fr) * | 1981-11-06 | 1983-05-18 | Imperial Chemical Industries Plc | Dérivés d'amide |
WO1998029199A1 (fr) * | 1996-12-31 | 1998-07-09 | Wayne Pigment Corp. | Composition pigmentaire inhibant les taches |
WO1999017777A1 (fr) * | 1997-10-08 | 1999-04-15 | Merck & Co., Inc. | Inhibiteurs de transferase de prenyl-proteine |
WO2000001382A1 (fr) * | 1998-07-02 | 2000-01-13 | Merck & Co., Inc. | Inhibiteurs de prenyl-proteine transferase |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003051366A2 (fr) | 2001-12-13 | 2003-06-26 | Abbott Laboratories | Inhibiteurs de kinase |
WO2003051366A3 (fr) * | 2001-12-13 | 2004-03-25 | Abbott Lab | Inhibiteurs de kinase |
US6831175B2 (en) | 2001-12-13 | 2004-12-14 | Abbott Laboratories | Kinase inhibitors |
JP2005511790A (ja) * | 2001-12-19 | 2005-04-28 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ファルネシルトランスフェラーゼ阻害剤としての炭素連結トリアゾールで置換されている1,8−アネル化キノリン誘導体 |
WO2004037791A1 (fr) | 2002-10-21 | 2004-05-06 | Chiron Corporation | Inhibiteurs de glycogene synthase kinase 3 |
US6989382B2 (en) | 2002-10-21 | 2006-01-24 | Chiron Corporation | Carbocycle based inhibitors of glycogen synthase kinase 3 |
US7745638B2 (en) | 2003-07-22 | 2010-06-29 | Astex Therapeutics Limited | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators |
US8779147B2 (en) | 2003-07-22 | 2014-07-15 | Astex Therapeutics, Ltd. | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators |
US9051278B2 (en) | 2003-07-22 | 2015-06-09 | Astex Therapeutics, Ltd. | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators |
US8080666B2 (en) | 2003-07-22 | 2011-12-20 | Astex Therapeutics, Ltd. | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators |
US7179827B2 (en) | 2004-03-31 | 2007-02-20 | Lexicon Genetics Incorporated | Thiazoles and methods of their use |
EP1734957A4 (fr) * | 2004-04-01 | 2009-06-17 | Pfizer Prod Inc | Composes de thiazole sulfamide utiles pour le traitement des maladies neurodegeneratives |
EP1734957A2 (fr) * | 2004-04-01 | 2006-12-27 | Pfizer Products Inc. | Composes de thiazole sulfamide utiles pour le traitement des maladies neurodegeneratives |
US8293767B2 (en) | 2005-01-21 | 2012-10-23 | Astex Therapeutics Limited | 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors |
US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
US8013163B2 (en) | 2005-01-21 | 2011-09-06 | Astex Therapeutics Limited | 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors |
US8952161B2 (en) | 2007-04-06 | 2015-02-10 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
US9422310B2 (en) | 2007-04-06 | 2016-08-23 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
US10336769B2 (en) | 2007-04-06 | 2019-07-02 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
US10941159B2 (en) | 2007-04-06 | 2021-03-09 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
US11713324B2 (en) | 2007-04-06 | 2023-08-01 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
US8710043B2 (en) | 2011-06-24 | 2014-04-29 | Amgen Inc. | TRPM8 antagonists and their use in treatments |
US8778941B2 (en) | 2011-06-24 | 2014-07-15 | Amgen Inc. | TRPM8 antagonists and their use in treatments |
US9096527B2 (en) | 2011-06-24 | 2015-08-04 | Amgen Inc. | TRPM8 antagonists and their use in treatments |
US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
US11299467B2 (en) | 2017-07-21 | 2022-04-12 | Antabio Sas | Chemical compounds |
Also Published As
Publication number | Publication date |
---|---|
JP2004509064A (ja) | 2004-03-25 |
HK1053833A1 (zh) | 2003-11-07 |
WO2001081316A3 (fr) | 2002-05-23 |
PE20011318A1 (es) | 2002-01-08 |
AU2001259218A1 (en) | 2001-11-07 |
MXPA02010608A (es) | 2003-05-14 |
CA2407093A1 (fr) | 2001-11-01 |
EP1276726A2 (fr) | 2003-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20020019527A1 (en) | Substituted phenyl farnesyltransferase inhibitors | |
EP1276726A2 (fr) | Inhibiteurs de phenyle farnesyltransferase substitues | |
RU2274639C2 (ru) | Производные замещенного триазолдиамина, фармацевтическая композиция на их основе и способ ее получения | |
AU2003249962B2 (en) | Inhibitors of tyrosine kinases | |
CA2200981A1 (fr) | Derives d'uree et leur utilisation comme inhibiteurs de l'acat | |
US6333324B1 (en) | Piperazine compounds as inhibitors of MMP or TNF | |
CN102459158B (zh) | 新的酰胺和脒衍生物和其用途 | |
US7323570B2 (en) | Farnesyltransferase inhibitors | |
DE60118955T2 (de) | Farnesyltransferase inhibitoren | |
EP0199845A1 (fr) | Dérivés d'imidazolylalkylguanidine, leur procédé de préparation et compositions les contenant | |
US20160228407A1 (en) | Novel 1,2- bis-sulfonamide derivatives as chemokine receptor modulators | |
AU2001297704B2 (en) | Farnesyltransferase inhibitors | |
MXPA05001985A (es) | Derivados de imidazol 2-tio-sustituidos y su uso en farmaceuticos. | |
AU2001297704A1 (en) | Farnesyltransferase inhibitors | |
AU2008202194B2 (en) | Inhibitors of tyrosine kinases | |
AU5412298A (en) | Piperazine compounds as inhibitors of mmp or tnf | |
AU2260500A (en) | Protease inhibitors - III |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2407093 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 578410 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/010608 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001932712 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001932712 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001932712 Country of ref document: EP |